acute ST-sEgment elevation myocardial infArction
Conditions
Interventions
treatment group:1ml of 100ug adenosine injection in 0.9% NaCl injection via suction catheter or micro-catheter in the distal part of the target lesion, followed by 2mg of adenosine injection, diluted
controp group:1ml of 0.9% NaCl injection was administered via a suction catheter or microcatheter in the distal segment of the target lesion by bullet injection, followed by a slow push of 10mL of 0.9
Sponsors
Zhongshan Hospital affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. age 18-75 years, either sex; 2. onset to entry time = 6 hours; 3. 2 or more adjacent anterior leads with an elevated ST segment = 0.2 mV; 4. coronary angiography confirms that the offender vessel is an anterior descending branch with occlusion or sub-total occlusion (TIMI flow grade 0-1) and no severe stenosis (<50% stenosis) in the remaining vessels; 5. consent to emergency PCI and no contraindications to the treatment; 6. agree to be enrolled in the clinical study and follow-up, and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. has received thrombolytic therapy; 2. has had a myocardial infarction or undergone revascularisation (PCI or CABG) within 6 months; 3. Severe bradyarrhythmias at presentation, e.g. atrioventricular block II-III, sick sinus node syndrome, history of prolonged Q-T interval, symptomatic persistent bradycardia (HR < 55 bpm) without pacemaker support; 4. previous history of bronchospasm or bronchial stenosis-related disease (e.g. chronic obstructive pulmonary disease, asthma, etc.); 5. patients with end-stage disease (e.g. advanced malignancy) and a life expectancy of less than 1 year; 6. women who are pregnant or breastfeeding; 7. patients who are allergic to adenosine injection or conventional medication; 8. patients who are participating in other interventional clinical studies or are considered by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myocardial infarct size measured by cardiac magnetic resonance (CMR) 7 days after PCI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of compound cardiovascular events include cardiovascular death, recurrent myocardial infarction, target vessel revascularisation and postoperative heart failure within 12 months after PCI;Proportion of complete ST-segment regression on ECG 90 minutes after PCI;TIMI blood flow frame count (cTFC) corrected immediately after PCI;Proportion of patients with MBG level 3 immediately after PCI;Proportion of no/slow flow in the immediate post-operative period after PCI;Peak cTnT, CK-MB and area under the curve at 6h, 12 and 24h after PCI;Serum NT-proBNP levels in 72 hours after PCI;Left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) measured by cardiac ultrasound 7 days after PCI;Percentage of myocardium at risk (AAR) measured by CMR 7 days after PCI;Myocardial salvage index (MSI) measured by CMR 7 days after PCI;Percentage of MVO at 7 days after PCI; | — |
Countries
China
Contacts
Public ContactJunbo Ge
Zhongshan Hospital affiliated to Fudan University
Outcome results
None listed